BGI Australia News Update

MOU signed on Collaborative Research and Innovation in Personalised Healthcare

BGI signs a Memorandum of Understanding (MoU) with the bio-nanotechnology innovator Xing Technologies, a UQ spin-off enterprise specialising in world-leading disease diagnosis and monitoring technologies, including cancer. The partnership will focus on collaborative research and product innovation in DNB technology, Circulating Tumour/Stem Cells technology, and point-of-care product. Keep reading

Independent Data Comparison of BGISEQ-500 to an Alternative System

Dr Andrew Carroll from DNAnexus conducted an independent side-by-side assessment of data comparison of BGISEQ 500 to Illumina NovaSeq on 2 Jul. 2018 and published the findings. The analysis is based on the three WGS data sets of NA12878/HG001 recently released, and demonstrates significant improvements relative to prior data. Keep reading

Collaborative Efforts With QAAFI (UQ) to Establish Australia's Gene Bank

BGI signed a Memorandum of Understanding with the University of Queensland to strengthen the extensive collaboration to establish Australia's very own gene bank. “This is an important initiative that will help protect the world’s biodiversity, and lead to other innovations in food security and human health.” said Professor Robert Henry, Director of the Queensland Alliance for Agriculture and Food Innovation. Keep reading

BGI Ranks the #1 Institution of the Most Academic Collaborations on Nature Index

On the latest Nature Index 2017 recently published, BGI ranks No.1 on the Top 50 Corporate Institutions by Number of Academic Collaborations with 642 bilateral collaborations worldwide from 2012 to 2016.  Other major multinational corporations are also named on the index e.g. Illumina, Inc. ranks the 6th with 412 collaborations; Thermo Fisher the 13th with 333 collaborations.  Keep reading

George Church Institute of Regenesis in China National Genebank

Professor George Church accepted the appointment as the Chief Scientist of the George Church Institute of Regenesis located in China National GeneBank, Shenzhen, China. BGI has made a strong commitment to support research directed by Prof. Church both in China and in the United States. The plan is to launch a series of projects starting from January 2018. The new collaboration of applied synthetic biology will initially focus on the development of enabling technologies in high-density DNA storage, biomanufacture of natural products, and genome editing for medicine and new therapy. Keep reading

BGI Genomics Officially Listed on Shenzhen Stock Exchange

BGI Genomics, an independent division of BGI Group, recently announced pricing of its initial public offering of 40.1 million shares at a list price of RMB 13.64 per share. Being a part of BGI Group,BGI Genomics provides a wide range of commercial next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research institutions and other public and private partners. Keep reading

BGI Australia Partners with the University of Queensland CAI

 Life Science research to benefit as global genomics specialist formalises ties with the University of Queensland Centre of Advanced Imaging (CAI) to develop early diagnostic tools for epilepsy.  “It will combine anatomical imaging data from Australia’s first ultra-high field 7T MRI with whole genome sequencing data from participants who have intractable focal epilepsy,” the Director of UQ CAI Professor David Reutens said "the research collaboration with BGI was unique and was set to boost the centre’s research, development and commercialisation." Keep reading 

BGI Australia and University of Melbourne to Expand Collaboration

BGI Australia and the University of Melbourne have signed a MOU to engage in scientific collaborations in the area of One Health using -omic and informatic technologies with the aim to build a comprehensive, world-class program and joint-centre in infectious diseases. Keep reading

BGI Australia Announced RFP Winners

Since the announcement of call for proposals in August 2017 BGI Australia has received 21 Expression of Interest(EOI)’s and 3 full proposals. We are sincerely appreciative of the extensive interest received from our passionate fellow Australian researchers and in the biodiversity and evolution fields. We are pleased to announce the final two winners: “Managing regime shifts and fisheries collapse on the Great Barrier Reef – the role of ancient DNA” from Professor John Pandolfi and Dr. Cynthia Riginos of the University of Queensland; and “Depth adaptation and scope for vertical connectivity in scleractinian corals” from Dr. Greg Torda of James Cook University. 

BGI Australia Laboratory Opened

Developed by global genomics company BGI, the BGISEQ-500 genomics sequencer (Zebra) will operate from the company’s new Australian headquarters at the QIMR Berghofer Medical Research Institute since May 2017. It is the only genomics sequencer of its kind in the Southern Hemisphere. Keep reading 

BGI Australia Office Opened

BGI today officially opened its new Australian and Asia Pacific headquarters at the QIMR Berghofer Medical Research Institute at Herston. BGI President and co-found Professor Jian Wang said the strength of Queensland’s existing life science institutions, industries and networks made it an obvious choice for BGI’s research and development, and commercialisation centre for the Asia Pacific region. Keep reading

QIMR Berghofer signs MOU with BGI Australia

QIMR Berghofer Medical Research Institute and the Chinese genomics organisation BGI have entered into an agreement that will promote collaboration on a genomics-based research and education program.  The Memorandum of Understanding was signed at a meeting between the two world-leading research bodies in October 2016 in Shenzhen. Keep reading